⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3439158 | 1.00 | — | — | |
| SCHEMBL25362832 | 0.82 | CYP2D6 (0.43) | — | |
| SCHEMBL3439209 | 0.78 | — | — | |
| SCHEMBL6720465 | 0.78 | — | — | |
| SCHEMBL2223466 | 0.78 | — | — | |
| SCHEMBL25352173 | 0.78 | — | — | |
| SCHEMBL3439112 | 0.78 | — | — | |
| SCHEMBL18787283 | 0.76 | — | — | |
| SCHEMBL5550787 | 0.74 | CYP2D6 (0.44) | — | |
| SCHEMBL6720564 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3914435-B2 | — | — | 2007-05-16 | — | — | JP | claimed |
| US-20050137414-A1 | New aminopropylphosphinic acids | ELEBRING THOMAS (SE) | 2005-06-23 | — | — | US | claimed |
| US-20030220303-A1 | New aminopropylphosphinic acids | ELEBRING THOMAS (SE) | 2003-11-27 | — | — | US | claimed |
| US-6596711-B1 | GABA B receptor agonists for use in the treatment of CNS disorders, such as muscle relaxation in spinal spasticity, cardiovascular disorders, asthma, gut motility disorders such as irritable bowel syndrome and gastroesophogeal reflux | ASTRAZENECA AB (SE) | 2003-07-22 | — | — | US | claimed |
| JP-2003516407-A | — | — | 2003-05-13 | — | — | JP | claimed |
| US-20020156053-A1 | New aminopropylphosphinic acids | GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT | 2002-10-24 | — | — | US | claimed |
| EP-1240172-A1 | NEW AMINOPROPYLPHOSPHINIC ACIDS | AstraZeneca AB (SE) | 2002-09-18 | — | — | EP | claimed |
| WO-2001042252-A1 | NEW AMINOPROPYLPHOSPHINIC ACIDS | ASTRAZENECA AB (SE) | 2001-06-14 | — | — | WO | claimed |
| US-7807658-B2 | Use of GabaB receptor agonists | ASTRAZENECA AB (SE) | 2010-10-05 | — | — | US | disclosed |
| US-20080146836-A1 | New Aminopropylphosphinic acids | ELEBRING THOMAS | 2008-06-19 | — | — | US | disclosed |
| US-20070021393-A1 | New use of GabaB receptor agonists | LEHMANN ANDERS | 2007-01-25 | — | — | US | disclosed |
| US-7034176-B2 | Aminopropylphosphinic acids | ASTRAZENECA AB (SE) | 2006-04-25 | — | — | US | disclosed |
| US-20050137414-A1 | New aminopropylphosphinic acids | ELEBRING THOMAS (SE) | 2005-06-23 | — | — | US | disclosed |
| US-6841698-B2 | GABAB Receptor Agonists; used to treat gastrointestinal disorders, especially GERD | ASTRAZENECA AB (SE) | 2005-01-11 | — | — | US | disclosed |
| US-6576626-B2 | Treating gastro-oesophageal reflux disease | ASTRAZENECA AB (SE) | 2003-06-10 | — | — | US | disclosed |
| US-20020156053-A1 | New aminopropylphosphinic acids | GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT | 2002-10-24 | — | — | US | disclosed |
| EP-1240172-A1 | NEW AMINOPROPYLPHOSPHINIC ACIDS | AstraZeneca AB (SE) | 2002-09-18 | — | — | EP | disclosed |
| EP-1239843-A1 | NEW (AMINOPROPYL)METHYLPHOSPHINIC ACIDS | AstraZeneca AB (SE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001042252-A1 | NEW AMINOPROPYLPHOSPHINIC ACIDS | ASTRAZENECA AB (SE) | 2001-06-14 | — | — | WO | disclosed |
| WO-2001041743-A1 | NEW (AMINOPROPYL)METHYLPHOSPHINIC ACIDS | ASTRAZENECA AB (SE) | 2001-06-14 | — | — | WO | disclosed |